• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

4.070 +0.040 (+0.99%)
Delayed Quote Updated: 3:59 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,367
Open 4.010
Bid (Size) 3.950 (100)
Ask (Size) 4.190 (100)
Prev. Close 4.030
Today's Range 3.875 - 4.300
52wk Range 2.430 - 21.60
Shares Outstanding 24,787,446
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
Today 9:00 EST
Third pharmaceutical company relationship entered 
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Celebrates its 70th Patent Award
October 28, 2026
New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension 
From Lexaria Bioscience Corp.
Via ACCESS Newswire

Performance

52-Week Range 81.2% below 52-week high
4.070
2.4352W Low 21.6052W High
1 Week 0.7% below 1-week high
3.061W Low 4.101W High

Lexaria Bioscience Corp. - Common Stock (LEXX) traded between $2.43 and $21.60 over the past 52 weeks and last traded at $4.07, 81.2% below its 52-week high. Over the past week it ranged between $3.06 and $4.10.

Past 12 Months
+23.3%
+46.9%
-27.6%
-60.8%
-58.5%
-73.9%
1W +$0.77
1M +$1.30
3M -$1.55
6M -$6.32
YTD -$5.74
1Y -$11.53

LEXX was -73.9% over the past year, -60.8% over six months, -58.5% year to date, +23.3% in the last week.

12 Months vs Market
LEXX
-73.9%
DIA
+12.6%
SPY
+12.2%
QQQ
+9.5%
IWM
+15.7%

Over the past 12 months LEXX returned -73.9% versus DIA (Dow) +12.6%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +9.5% and IWM (Russell 2000) +15.7%.

Volume & Liquidity 0.44× 3-mo avg
Today 32,367 3-mo avg 74.2K
1W
34.4K
1M
56.7K
3M
74.2K
6M
41.9K
YTD
30.4K
1Y
34.4K

LEXX most recently traded 32,367 shares against a 3-month average daily volume of 74.2K.

More News

Read More
News headline image
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
October 21, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Results from Animal Study GLP-1-A26-1
October 15, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Results From Animal Study GLP-1-A26-1
October 15, 2026
Via TheNewswire.com
Topics Intellectual Property
News headline image
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
October 06, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Updates Financial Position
September 17, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 09, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
September 09, 2026
Via TheNewswire.com
News headline image
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 08, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 04, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
Via TheNewswire.com
News headline image
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
August 24, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Updates Business Development
July 06, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 09, 2026
Via ACCESS Newswire
News headline image
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 03, 2026
Via ACCESS Newswire
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via ACCESS Newswire
News headline image
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via ACCESS Newswire
News headline image
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via ACCESS Newswire

Frequently Asked Questions

Is Lexaria Bioscience Corp. - Common Stock publicly traded?
Yes, Lexaria Bioscience Corp. - Common Stock is publicly traded.
What exchange does Lexaria Bioscience Corp. - Common Stock trade on?
Lexaria Bioscience Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexaria Bioscience Corp. - Common Stock?
The ticker symbol for Lexaria Bioscience Corp. - Common Stock is LEXX on the Nasdaq Stock Market
What is the current price of Lexaria Bioscience Corp. - Common Stock?
The current price of Lexaria Bioscience Corp. - Common Stock is 4.070
When was Lexaria Bioscience Corp. - Common Stock last traded?
The last trade of Lexaria Bioscience Corp. - Common Stock was at 11/04/26 03:59 PM ET
What is the market capitalization of Lexaria Bioscience Corp. - Common Stock?
The market capitalization of Lexaria Bioscience Corp. - Common Stock is 100.88M
How many shares of Lexaria Bioscience Corp. - Common Stock are outstanding?
Lexaria Bioscience Corp. - Common Stock has 101M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap